Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.
18F-DOPA
18F-FDG
68Ga-DOTA peptides
Medullary thyroid carcinoma
Molecular imaging
Nuclear medicine
PET
Theranostics
Journal
Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588
Informations de publication
Date de publication:
16 Sep 2023
16 Sep 2023
Historique:
accepted:
05
09
2023
medline:
16
9
2023
pubmed:
16
9
2023
entrez:
15
9
2023
Statut:
aheadofprint
Résumé
Due to its rarity and non-specific clinical presentation, accurate diagnosis, and optimal therapeutic strategy of medullary thyroid carcinoma (MTC) remain challenging. Molecular imaging provides valuable tools for early disease detection, monitoring treatment response, and guiding personalized therapies. By enabling the visualization of molecular and cellular processes, these techniques contribute to a deeper understanding of disease mechanisms and the development of more effective clinical interventions. Different nuclear imaging techniques have been studied for assessing MTC, and among them, PET/CT utilizing multiple radiotracers has emerged as the most effective imaging method in clinical practice. This review aims to provide a comprehensive summary of the current use of advanced molecular imaging modalities, with a particular focus on PET/CT, for the management of patients with MTC. It aims to guide physicians towards a rationale for the use of molecular imaging also including theranostic approaches and novel therapeutical opportunities. Overall, we emphasize the evolving role of nuclear medicine in MTC. The integration of diagnostics and therapeutics by in vivo molecular imaging represents a major opportunity to personalize treatment for individual patients, with targeted radionuclide therapy being one representative example.
Identifiants
pubmed: 37715050
doi: 10.1007/s11154-023-09836-y
pii: 10.1007/s11154-023-09836-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab. 1959;19:152–61.
pubmed: 13620740
Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450–5.
pubmed: 17119000
Essig GF Jr, Porter K, Schneider D, Arpaia D, Lindsey SC, Busonero G, Fineberg D, Fruci B, Boelaert K, Smit JW, Meijer JA, Duntas LH, Sharma N, Costante G, Filetti S, Sippel RS, Biondi B, Topliss DJ, Pacini F, Maciel RM, Walz PC, Kloos RT. Thyroid. 2016;26:1563–72.
pubmed: 27604949
pmcid: 6453487
Trimboli P, Mian C, Piccardo A, Treglia G. Diagnostic tests for medullary thyroid carcinoma: an umbrella review. Endocrine. 2023;6 (ahead of print).
Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmayer C, Haas OA, Niederle B. Endocr Relat Cancer. 2009;16:243–53.
pubmed: 18987170
Machens A, Dralle H. Biological relevance of medullary thyroid microcarcinoma. J Clin Endocrinol Metab. 2012;97:1547–53.
pubmed: 22399508
Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1995;42:581–8.
Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML. Multiple endocrine neoplasms. Best Pract Res Clin Rheumatol. 2008;22:149–63.
pubmed: 18328987
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575–9.
pubmed: 8918855
Moley JF. (2010) Medullary thyroid carcinoma: Management of lymph node metastases. J Natl Compr Canc Netw. 2010;8:549–556.
Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised american thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.
pubmed: 25810047
pmcid: 4490627
Pazaitou-Panayiotou K, Chrisoulidou A, Mandanas S, Tziomalos K, Doumala E, Patakiouta F. Predictive factors that influence the course of medullary thyroid carcinoma. Int J Clin Oncol. 2014;19:445–51.
pubmed: 23832286
Mehrotra PK, Mishra A, Mishra SK, Agarwal G, Agarwal A, Verma AK. Medullary thyroid Cancer: clinico-pathological Profile and Outcome in a Tertiary Care Center in North India. World J Surg. 2011;35:1273–80.
pubmed: 21479684
Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4:64–71.
pubmed: 26608066
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639–46.
pubmed: 24002501
pmcid: 4164813
Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134–41.
pubmed: 22025146
Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017;28:2813–9.
pubmed: 29045520
pmcid: 5834040
Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, et al. Genetic Landscape of somatic mutations in a large cohort of sporadic medullary thyroid Carcinomas studied by next-generation targeted sequencing. iScience. 2019;20:324–36.
pubmed: 31605946
pmcid: 6817656
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9:491–501.
pubmed: 34118198
10, Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of Selpercatinib in RET-Altered thyroid cancers. N Engl J Med. 2020;383:825–35.
Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d’Etude des Tumeurs a calcitonine (GETC). Br J Cancer. 1995;71:363–5.
pubmed: 7530987
pmcid: 2033569
Wang L, Kou H, Chen W, Lu M, Zhou L, Zou C. The diagnostic value of Ultrasound in Medullary thyroid carcinoma: a comparison with computed tomography. Technol Cancer Res Treat. 2020;19:153303382090583.
Liu MJ, Liu ZF, Hou YY, Men YM, Zhang YX, Gao LY, Liu H. Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Oncotarget. 2017;8:27520–8.
pubmed: 28460476
pmcid: 5432354
Lai X, Liu M, Xia Y, Wang L, Bi Y, Li X, Zhang B, Yang M, Dai Q, Jiang Y. Hypervascularity is more frequent in medullary thyroid carcinoma: compared with papillary thyroid carcinoma. Medicine. 2016;95:e5502.
pubmed: 27930537
pmcid: 5266009
Valderrabano P, Klippenstein DL, Tourtelot JB, Ma Z, Thompson ZJ, Lilienfeld HS, McIver B. New american thyroid Association Sonographic patterns for thyroid nodules perform well in medullary thyroid carcinoma: institutional experience, systematic review, and Meta-Analysis. Thyroid. 2016;26:1093–100.
pubmed: 27267210
pmcid: 7871990
Ferrarazzo G, Camponovo C, Deandrea M, Piccardo A, Scappaticcio L, Trimboli P. Suboptimal accuracy of ultrasound and ultrasound-based risk stratification systems in detecting medullary thyroid carcinoma should not be overlooked. Findings from a systematic review with meta-analysis. Clin Endocrinol (Oxf). 2022;97:532–40.
pubmed: 35419855
Trimboli P, Castellana M, Piccardo A, Romanelli F, Grani G, Giovanella L, Durante C. The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis. Rev Endocr Metab Disord. 2021;22:453–60.
pubmed: 32959174
Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid Cancer. J Clin Endocrinol Metab. 2010;95:2655–63.
pubmed: 20339026
Klain M, Hadoux J, Nappi C, Finessi M, Ambrosio R, Schlumberger M, Cuocolo A, Deandreis D, Salvatore D. Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives. Endocrine. 2022;75:330–7.
pubmed: 34748168
Debnam JM, Guha-Thakurta N, Sun J, Wei W, Zafereo ME, Cabanillas ME, Buisson NM, Schellingerhout D. Distinguishing recurrent thyroid Cancer from residual nonmalignant thyroid tissue using multiphasic multidetector CT. AJNR Am J Neuroradiol. 2020;41:844–51.
pubmed: 32327435
pmcid: 7228186
Fitzgerald RT, Kuruva M, David R, Samant RS, Kumar M, Van Hemert R, Angtuaco EJ, Bodenner D, Stack BC Jr. Characterization of thyroid nodules by 4-Dimensional Computed Tomography: initial experience. J Comput Assist Tomogr. 2017;41:195–8.
pubmed: 27560025
Gürsoy Çoruh A, Uzun Ç, Kul M, Akkaya Z, Halil Elhan A, Gökcan K. The impact of arterial phase on the detection of cervical lymph node metastasis from papillary thyroid carcinoma: a quantitative evaluation on multiphasic computed tomography. J Comput Assist Tomogr. 2020;44:262–8.
pubmed: 32195806
Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353:1105–13.
pubmed: 16162881
Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:61–77.
pubmed: 31482429
Castinetti F, Taïeb D. Positron emission tomography imaging in medullary thyroid carcinoma: time for reappraisal? Thyroid. 2021;31:151–5.
pubmed: 33191866
Treglia G, Sadeghi R, Giovinazzo F, Galiandro F, Annunziata S, Muoio B, Kroiss AS. PET with different radiopharmaceuticals in neuroendocrine neoplasms: an umbrella review of published meta-analyses. Cancers. 2021;13:5172.
pubmed: 34680321
pmcid: 8533943
Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, Montravers F. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33:775–9.
pubmed: 22546877
Fargette C, Imperiale A, Taïeb D. Molecular imaging of endocrine neoplasms with emphasis on 18F-DOPA PET: a practical approach for well-tailored imaging protocols. Q J Nucl Med Mol Imaging. 2022;66:141–7.
pubmed: 35343670
Rasul S, Hartenbach S, Rebhan K, Göllner A, Karanikas G, Mayerhoefer M, Mazal P, Hacker M, Hartenbach M. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur J Nucl Med Mol Imaging. 2018;45:2159–69.
pubmed: 29766245
pmcid: 6182401
Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A. Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1856–83.
pubmed: 31549998
Beheshti M, Pocher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfurst S, Pirich C, Dralle H, Langsteger W. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19:1425–34.
pubmed: 19156423
Brammen L, Niederle MB, Riss P, Scheuba C, Selberherr A, Karanikas G, Bodner G, Koperek O, Niederle B. Medullary thyroid carcinoma: do Ultrasonography and F-DOPA-PET-CT influence the initial Surgical Strategy? Ann Surg Oncol. 2018;25:3919–27.
pubmed: 30306375
pmcid: 6245031
Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71.
pubmed: 11202454
Treglia G, Rufini V, Piccardo A, Imperiale A. Update on management of medullary thyroid carcinoma: focus on Nuclear Medicine. Semin Nucl Med. 2023 (Ahead of print).
Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1604–9.
pubmed: 17435996
Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527–33.
pubmed: 20450432
Treglia G, Cocciolillo F, Di Nardo F, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19:1290–9.
pubmed: 22819076
Archier A, Heimburger C, Guerin C, Morange I, Palazzo FF, Henry JF, Schneegans O, Mundler O, Abdullah AE, Sebag F, Imperiale A, Taieb D. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:1027–33.
pubmed: 26497699
Rotania M, Chabrier G, Imperiale A. Synchronous bilateral pheochromocytomas and bilobar medullary thyroid carcinoma revealed by 18F-FDOPA PET/CT in a MEN-2A asymptomatic patient. Endocrine. 2019;66:691–2.
pubmed: 31478160
Terroir M, Caramella C, Borget I, Bidault S, Dromain C, El Farsaoui K, Deandreis D, Grimaldi S, Lumbroso J, Berdelou A, Hadoux J, Hescot S, Hartl D, Baudin E, Schlumberger M, Leboulleux S. F-18-Dopa positron emission tomography/computed tomography is more sensitive than whole-body magnetic resonance imaging for the localization of persistent/recurrent disease of medullary thyroid cancer patients. Thyroid. 2019;29:1457–64.
pubmed: 31530235
Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012;42:535–45.
pubmed: 22527889
Cheng X, Bao L, Xu Z, Li D, Wang J, Li Y. 18F-FDG-PET and 1-F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2012;56:136–42.
pubmed: 22498184
Caobelli F, Chiaravalloti A, Evangelista L, Saladini G, Schillaci O, Vadrucci M, Scalorbi F, Donner D, Alongi P, Young AIMN, Working Group. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann Nucl Med. 2018;32:7–15.
pubmed: 28986764
Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. ., and american thyroid Association Guidelines Task Force on Medullary thyroid carcinoma. Medullary thyroid cancer: management guidelines of the american thyroid Association. Thyroid. 2009;19:565–612.
pubmed: 19469690
Skoura E, Datseris IE, Rondogianni P, Tsagarakis S, Tzanela M, Skilakaki M, Exarhos D, Alevizaki M. Correlation between calcitonin levels and [(18)F]FDG-PET/CT in the detection of recurrence in patients with sporadic and Hereditary Medullary thyroid Cancer. ISRN Endocrinol. 2012;2012:375231.
pubmed: 22655204
pmcid: 3357961
Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.
pubmed: 17726071
Treglia G, Goichot B, Giovanella L, Hindié E, Jha A, Pacak K, Taïeb D, Walter T, Imperiale A. Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine. 2020;67:9–19.
pubmed: 31734779
Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, Fanti S, Gross MD, Al-Nahhas A, Rubello D. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414–21.
pubmed: 20100647
Salaun PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, Bournaud C, Vuillez JP, Taieb D, Rousseau C, Drui D, Mirallié E, Borson-Chazot F, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F. 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1501–10.
pubmed: 24806110
Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, Aulmann C, Fassnacht M, Kroiss M, Reiners C, Buck AK, Kreissl MC, Lapa C. Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. J Nucl Med. 2018;59:756–61.
pubmed: 29025983
Werner RA, Bundschuh RA, Higuchi T, Javadi MS, Rowe SP, Zsótér N, Kroiss M, Fassnacht M, Buck AK, Kreissl MC, Lapa C. Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. Endocrine. 2019;63:293–300.
pubmed: 30206772
Puhr-Westerheide D, Cyran CC, Sargsyan-Bergmann J, Todica A, Gildehaus FJ, Kunz WG, Stahl R, Spitzweg C, Ricke J, Kazmierczak PM. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging. 2019;14:19:73.
Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, Ambrosini V, Cremonini N, Santimaria M, Versari A, Fanti S, Giordano A, Rufini V. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569–80.
pubmed: 22223169
Yamaga LYI, Cunha ML, Campos Neto GC, Garcia MRT, Yang JH, Camacho CP, Wagner J, Funari MBG. (68)Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging. 2017;44:1695–701.
pubmed: 28429044
Lee SW, Shim SR, Jeong SY, Kim SJ. Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a Network Meta-analysis. Clin Nucl Med. 2020;45:341–8.
pubmed: 32049723
Pajak C, Cadili L, Nabata K, Wiseman SM. 68Ga-DOTATATE-PET shows promise for diagnosis of recurrent or persistent medullary thyroid cancer: a systematic review. Am J Surg. 2022;224:670–5.
pubmed: 35382933
Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens Greece). 2017;16:262–72.
Reubi JC, Waser B, Maecke HR, Rivier JE. Highly increased 125i-Jr11 antagonist binding in vitro reveals novel indications for Sst2 targeting in human cancers. J Nucl Med. 2016;58:300–6.
pubmed: 27561878
Imperiale A, Jha A, Meuter L, Nicolas GP, Taïeb D, Pacak K. The emergence of somatostatin antagonist-based theranostics: paving the Road toward another success? J Nucl Med. 2023;64:682–4.
pubmed: 36759198
Ueda CE, Duarte PS, de Castroneves LA, Coura-Filho GB, Sado HN, Sapienza MT, Hoff AO, Buchpiguel CA. Comparison of 18F-NaF PET/CT with other imaging methods in the detection of bone metastases in patients with medullary thyroid cancer: a report of a series of 31 cases. Nucl Med Mol Imaging. 2020;54:281–91.
pubmed: 33281999
pmcid: 7704988
Ueda CE, Duarte PS, de Castroneves LA, Flávio J, Marin G, Sado HN, Sapienza MT, Hoff AO, Buchpiguel CA. Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer. Nucl Med Commun. 2020;41:469–760.
pubmed: 32187160
Li C, Zhang P, Nie R, Gong X, Xie J, Yu Z, Wang C, Zhang H, Yan R, Lu Z. Targeting amyloids with [18F]AV-45 for medullary thyroid carcinoma positron emission tomography/computed tomography imaging: a pilot clinical study. Mol Pharm. 2022;19:584–91.
pubmed: 34982563
pmcid: 8826757
Jamsek J, Hocevar M, Bergant D, Zaletel K, Rep S, Lezaic L. Diagnostic value of [18F]Fluorocholine PET/CT in detection of primary medullary thyroid cancer. Ann Nucl Med. 2021;35:429–37.
pubmed: 33544320
Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, Kim SW, Chung JH. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr J. 2010;57:1045–54.
pubmed: 20978365
Uprimny C, von Guggenberg E, Svirydenka A, Mikołajczak R, Hubalewska-Dydejczyk A, Virgolini IJ. Comparison of PET/CT imaging with FDOPA and cholecystokinin-2 receptor targeting 68Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:935–6.
pubmed: 32748048
Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177Lu-DOTA-PP-F11N:does the use of protease inhibitors further improve in vivo distribution? J Nucl Med. 2019;60:393–9.
pubmed: 30002107
von Guggenberg E, Uprimny C, Klingler M, Warwitz B, Sviridenko A, Bayerschmidt S, Di Santo G, Virgolini IJ. Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer. J Nucl Med. 2023 (Ahead of print).
Wong JYC, Yamauchi DM, Adhikarla V, Simpson J, Frankel PH, Fong Y, Melstrom KA, Chen YJ, Salehian BD, Woo Y, Dandapani SV, Colcher DM, Poku EK, Yazaki PJ, Wu AM, Shively JE. First-In-human pilot PET immunoimaging study of 64Cu-anti-carcinoembryonic antigen monoclonal antibody (hT84.66-M5A) in patients with carcinoembryonic antigen-producing cancers. Cancer Biother Radiopharm. 2023;38:26–37.
pubmed: 36154291
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, Toulgoat F, Masson D, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Anti-CEA pretargeted immuno-PET shows higher sensitivity than DOPA PET/CT in detecting relapsing metastatic medullary thyroid carcinoma: Post hoc analysis of the iPET-MTC study. J Nucl Med. 2021;62:1221–7.
pubmed: 33547213
pmcid: 8882894
Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, Faivre-Chauvet A, Barbet J, Rousseau C, Kraeber-Bodéré F. Clinical results in medullary thyroid carcinoma suggest high potential of pretargeted immuno-PET for tumor imaging and theranostic approaches. Front Med. 2019;6:124.
Ballal S, Yadav MP, Moon ES, Rösch F, ArunRaj ST, Agarwal S, Tripathi M, Sahoo RK, Bal C. First-in-human experience with 177Lu-DOTAGA.(SA.FAPi)2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer. Clin Nucl Med. 2022;47:e444–5.
pubmed: 35507435
Kuyumcu S, Isık EG, Sanli Y. Liver metastases from medullary thyroid carcinoma detected on 68Ga-FAPI-04 PET/CT. Endocrine. 2021;74:727–8.
pubmed: 34169462
Ballal S, Yadav MP, Roesch F, Raju S, Satapathy S, Sheokand P, Moon ES, Martin M, Agarwal S, Tripathi M, Bal C. Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC PET/CT imaging for the follow-up surveillance of patients with medullary thyroid cancer. Thyroid. 2023;12 (Ahead of print).
Arora S, Damle NA, Parida GK, Singhal A, Nalli H, Dattagupta S, Bal C. Recurrent medullary thyroid carcinoma on 68Ga-prostate-specific membrane antigen PET/CT: exploring new theranostic avenues. Clin Nucl Med. 2018;43:359–60.
pubmed: 29485449
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:925–51.
pubmed: 35948029
Hofland J, Brabander T, Verburg FA, Feelders RA, de Herder WW. Peptide receptor Radionuclide Therapy. J Clin Endocrinol Metab. 2022;107:3199–208.
pubmed: 36198028
pmcid: 9693835
Czajkowski M, Kaemmerer D, Sänger J, Sauter G, Wirtz RM, Schulz S, Lupp A. Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies. BMC Cancer. 2022;7:22:740.
Hayes AR, Crawford A, Al Riyami K, Tang C, Bomanji J, Baldeweg SE, Wild D, Morganstein D, Harry A, Grozinsky-Glasberg S, Oleinikov K, Khoo B, Caplin ME, Nicolas GP, Grossman AB. Metastatic medullary thyroid Cancer: the role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and peptide receptor Radionuclide Therapy. J Clin Endocrinol Metab. 2021;106:e4903–16.
pubmed: 34379772
Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer. 2021;20:21:579.
Liu Q, Kulkarni HR, Zhao T, Schuchardt C, Chen X, Zhu Z, Zhang J, Baum RP. Peptide receptor Radionuclide Therapy in patients with Advanced Progressive Medullary thyroid Cancer: efficacy, Safety, and survival predictors. Clin Nucl Med. 2023;48:221–7.
pubmed: 36723881
von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R, Hubalewska-Dydejczyk A. Update on Preclinical Development and clinical translation of Cholecystokinin-2 receptor targeting Radiopharmaceuticals. Cancers (Basel). 2021;18:13:5776.
Hasenauer N, Higuchi T, Deschler-Baier B, Hartrampf PE, Pomper MG, Rowe SP, Fassnacht M, Buck AK, Werner RA. Visualization of Tumor Heterogeneity in Advanced Medullary thyroid carcinoma by Dual-Tracer Molecular Imaging: revealing the Theranostic potential of SSTR- and PSMA-Directed Endoradiotherapy. Clin Nucl Med. 2022;47:651–2.
pubmed: 35085172
Martin M, Ballal S, Yadav MP, Bal C, Van Rymenant Y, De Loose J, Verhulst E, De Meester I, Van Der Veken P, Roesch F. Novel generation of FAP inhibitor-based homodimers for Improved Application in Radiotheranostics. Cancers (Basel). 2023;21;15:1889.
Kim M, Kim BH. Current guidelines for management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2021;36:514–24.
pubmed: 34154310